Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesGRI Bio Inc.

GRI Bio Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.87 USD -0.01 ( 0.53%)
Last update at 2026-11-09T15:36:00Z
VOLUME
18999
Market Cap
3.98M

Momentum Score

…

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.79
Low
1.88
High
52 Week Price Range
1.36
Low
64.12
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1.88
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.01
ROE
-142.02%
Net Debt
-8.16M
ROCE
-198.85%
Diluted EPS TTM
-2.71

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -11.96M -8.21M -13.04M -3.22M -1.56M
Net income -11.96M -8.21M -13.04M -3.54M -1.51M
Selling general administrative 5.16M 4.41M 8.78M 2.00M 0.81M
Selling and marketing expenses - 0.06M - - -
Gross profit -0.00M -0.00M -0.06M -0.21M -0.07M
Reconciled depreciation 0.00M 0.00M 0.05M 0.05M 0.05M
Ebit -11.98M -8.21M -11.39M -2.24M -1.06M
Ebitda -11.97M -8.20M -11.33M -2.19M -1.01M
Depreciation and amortization 0.00M 0.00M 0.06M 0.05M 0.05M
Operating income -11.98M -8.23M -11.39M -2.24M -1.06M
Other operating expenses 11.98M 8.23M 11.39M 2.24M 1.06M
Interest expense - 0.01M 2.08M 0.65M 0.55M
Interest income 0.02M 0.03M - - -
Net interest income 0.02M 0.03M -2.37M -0.65M -0.55M
Income tax expense - - - 0.33M -0.05M
Total revenue 0.00M 22.54M 0.00M 0.00M 0.00M
Total operating expenses 11.98M 8.23M 11.33M 2.24M 1.06M
Cost of revenue 0.00M 0.00M 0.06M 0.21M 0.07M
Total other income expense net 0.02M 0.03M -1.65M -0.98M -0.50M
Net income from continuing ops -11.96M -8.21M -13.30M -3.22M -1.56M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 8.67M 5.74M 2.96M 0.38M 0.22M
Other current assets 0.36M 0.59M 1.13M 0.30M 0.01M
Total liab 2.66M 1.71M 2.70M 2.01M 4.94M
Total stockholder equity 6.01M 4.03M 0.26M -1.62M -4.72M
Other current liab 0.75M 0.69M 1.27M 0.04M 1.27M
Common stock - - - 0.27M 0.35M
Capital stock 0.00M 0.00M 0.00M 0.27M 0.35M
Retained earnings -51.70M -39.74M -31.53M -18.50M -15.28M
Other assets - - 0.00M - -
Cash 8.23M 5.03M 1.81M 0.01M 0.09M
Total current liabilities 2.64M 1.64M 2.70M 1.99M 4.88M
Net debt -8.16M -4.91M -1.79M 0.66M 3.52M
Short term debt 0.06M 0.05M 0.01M 0.66M 3.55M
Short long term debt - - - 0.60M 3.50M
Short long term debt total 0.07M 0.12M 0.01M 0.67M 3.61M
Other stockholder equity 57.70M 43.77M 31.79M 16.60M 10.20M
Total current assets 8.59M 5.62M 2.93M 0.31M 0.10M
Accounts payable 1.84M 0.90M 1.41M 1.29M 0.06M
Non currrent assets other - - -0.00M 0.00M 0.01M
Non current assets total 0.07M 0.12M 0.02M 0.07M 0.12M
Capital lease obligations 0.07M 0.12M 0.01M 0.07M 0.11M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M -0.01M -0.00M 0.00M
Total cashflows from investing activities -0.00M - - - -
Net borrowings - 0.00M - - -
Total cash from financing activities 13.39M 11.83M 10.95M 1.01M 0.60M
Net income -11.96M -8.21M -13.04M -3.22M -1.56M
Change in cash 3.20M 3.22M 1.80M -0.08M -0.25M
Begin period cash flow 5.03M 1.81M 0.01M 0.09M 0.34M
End period cash flow 8.23M 5.03M 1.81M 0.01M 0.09M
Total cash from operating activities -10.19M -8.61M -9.14M -1.08M -0.85M
Issuance of capital stock 15.56M 13.10M 1.25M 12.25M 0.10M
Depreciation 0.00M 0.00M 0.06M 0.05M 0.05M
Other cashflows from investing activities - 0.40M - - -
Dividends paid - - - 3.45M -
Sale purchase of stock -0.00M -0.00M 0.00M -0.12M 0.00M
Other cashflows from financing activities -2.17M -1.27M -2.05M 1.38M 0.74M
Capital expenditures 0.00M 0.00M 0.01M 0.00M 0.00M
Change in working capital 0.93M -0.45M 1.68M 1.51M 0.56M
Stock based compensation 0.79M 0.15M 0.39M 0.03M 0.00M
Other non cash items 0.05M -0.11M 0.12M 0.22M 0.10M
Free cash flow -10.19M -8.61M -9.15M -1.09M -0.85M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
GRI
GRI Bio Inc.		 -0.01
0.53%		 1.87 - - - 0.40
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12

Profile*

GRI Bio Inc.

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

2223 Avenida de la Playa, La Jolla, CA, United States, 92037

619 400 1170

https://www.gribio.com

3

Name Title Year Born
Dr. W. Marc Hertz Ph.D. Co-Founder, CEO, President & Director 1971
Ms. Leanne M. Kelly CFO & Corporate Secretary 1977
Dr. Vipin Kumar Chaturvedi Ph.D. Co-Founder & Chief Scientific Officer 1960
Dr. Albert Agro Ph.d. Chief Medical Officer 1965
Dr. Albert Agro Ph.D. Co-Founder & Chief Medical Officer 1965

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.63%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.18%

  • Financial Services

    +1.33%

  • Healthcare

    +1.49%

  • Industrials

    +2.99%

  • Real Estate

    +0.41%

  • Technology

    +1.45%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…